Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total transaction of $5,525,485.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,563,576.19. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $5.46 during mid-day trading on Thursday, reaching $564.81. The company’s stock had a trading volume of 830,972 shares, compared to its average volume of 495,835. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $607.89. The stock has a market capitalization of $24.76 billion, a P/E ratio of 20.24, a P/E/G ratio of 1.72 and a beta of 0.75. The stock has a 50-day moving average of $502.93 and a two-hundred day moving average of $476.94.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted $6.19 earnings per share. Analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso IPF data remains the main bullish catalyst: the trial met its key endpoint, which drove a strong rally earlier this week and materially improves the drug’s commercial and pipeline upside. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Analyst support increased: HC Wainwright reiterated a Buy and raised some near‑term EPS estimates (and maintains a $660 price target), signaling confidence in the outlook after the clinical readout. This underpins further upside expectations. United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: Unusually high options activity indicates elevated speculative/hedging interest — can amplify intraday moves but is ambiguous for longer‑term direction. Monitor open interest and whether activity is skewed to calls or puts. United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Mixed analyst/media coverage on valuation: some outlets are assessing upside given the Tyvaso win, while broader analyst surveys remain cautious/neutral — suggesting sentiment is mixed and price action may hinge on follow‑up commercial guidance and modeling. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Insider selling by the CEO and CFO: Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares on March 30 — sizable disposals that reduced their holdings materially and may be viewed negatively by some investors (though insiders sell for many reasons). SEC filings detail the transactions. SEC filing — Rothblatt sale SEC filing — Edgemond sale

Analyst Ratings Changes

Several analysts have recently weighed in on UTHR shares. UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $586.00.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in UTHR. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its position in United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new position in United Therapeutics in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.